Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 5.99% | 2.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.99% | 2.31% | |||
| Cost of Revenue | 3.67% | -0.69% | |||
| Gross Profit | 16.12% | 17.82% | |||
| SG&A Expenses | 3.03% | -26.17% | |||
| Depreciation & Amortization | -2.64% | 1.62% | |||
| Other Operating Expenses | 52.99% | 3.16% | |||
| Total Operating Expenses | 3.58% | -3.66% | |||
| Operating Income | 36.32% | 365.16% | |||
| Income Before Tax | 47.17% | 727.99% | |||
| Income Tax Expenses | 652.66% | 301.99% | |||
| Earnings from Continuing Operations | -5.78% | 869.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -112.03% | 538.89% | |||
| Net Income | -8.60% | 854.88% | |||
| EBIT | 36.32% | 365.16% | |||
| EBITDA | 24.86% | 126.60% | |||
| EPS Basic | -8.27% | 856.73% | |||
| Normalized Basic EPS | 46.25% | 530.26% | |||
| EPS Diluted | -8.27% | 747.00% | |||
| Normalized Diluted EPS | 46.42% | 522.05% | |||
| Average Basic Shares Outstanding | -0.36% | -0.09% | |||
| Average Diluted Shares Outstanding | -0.36% | 1.75% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 0.09% | 1.13% | |||